title: Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
abstract: OBJECTIVE
  To evaluate the efficiency of Coleman lipostructure in patients infected with human immunodeficiency virus (HIV).
  
  
  METHODS
  Open-label study and survey.
  
  
  METHODS
  Ambulatory dermatosurgery department of a university hospital.
  
  
  METHODS
  Thirty-three consecutive HIV-infected patients undergoing Coleman lipostructure between 2000 and 2001.
  
  
  METHODS
  Clinical examination, blood tests, and standardized photographs at baseline and 1 year after the lipostructure.
  
  
  METHODS
  Efficiency was assessed by the agreement of 3 independent medical specialists on facial lipodystrophy improvement after surgery and by patient satisfaction.
  
  
  RESULTS
  Facial lipoatrophy was improved in 12 patients (36%; 95% confidence interval, 20%-52%) as judged by all 3 evaluators. Quantity of fat injected (P = .01) and a low serum triglyceride level before surgery (P = .03) were significantly associated with improvement of facial lipoatrophy. Of the 33 patients, 14 (43%) were very satisfied, 17 (50%) were partly satisfied, and 27 (81%) had a better quality of life. The most common comment was that the patient looked better and appeared less ill.
  
  
  CONCLUSIONS
  Our 1-year evaluation of Coleman lipostructure for correction of facial lipoatrophy in HIV-infected patients proved the efficiency of this treatment when measured conservatively by agreement on improvement by 3 independent specialists and demonstrated a patient satisfaction rate of 93%.
authors.affiliation: Service de Dermatologie, Hôpital Tarnier-Cochin, Paris, France.
authors.forename: Marielle
authors.initials: M
authors.lastname: Burnouf
authors.forename: Marc
authors.initials: M
authors.lastname: Buffet
authors.forename: Michaël
authors.initials: M
authors.lastname: Schwarzinger
authors.forename: Philippe
authors.initials: P
authors.lastname: Roman
authors.forename: Patrick
authors.initials: P
authors.lastname: Bui
authors.forename: Marianne
authors.initials: M
authors.lastname: Prévot
authors.forename: Jean
authors.initials: J
authors.lastname: Deleuze
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Morini
authors.forename: Nathalie
authors.initials: N
authors.lastname: Franck
authors.forename: Isabelle
authors.initials: I
authors.lastname: Gorin
authors.forename: Nicolas
authors.initials: N
authors.lastname: Dupin
mesh_terms: D000273:Adipose Tissue / Q000637:transplantation*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D008060:Lipodystrophy / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D014182:Transplantation, Autologous / Q000009:adverse effects; D016896:Treatment Outcome